Valiant Laboratories Ltd

Valiant Laboratories Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in securities of the company will be closed for directors, promoters, designated persons, their immediate relatives, and connected persons, effective October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, in accordance with SEBI regulations and the company’s code of conduct.

Valiant Laboratories Limited announced that its board approved an investment of up to Rs 70 lakh to acquire shares in AMPYR Renewable Energy Resources Twelve A Private Limited, a subsidiary of AMPYR India Asset Holdings Two Pte. Ltd., Singapore, to procure solar power for its Tarapur plant under a group captive open access arrangement. The acquisition, expected to be completed within 12 months, will result in Valiant Laboratories holding up to 1.01% of the Equity Share Capital and up to 3.60% of the Compulsorily Convertible Preference Shares of AMPYR, which was incorporated on November 1, 2023, and has a turnover of Rs 23.26 crore for the fiscal year 2025-26.

Valiant Laboratories Limited announced that its board approved an investment of up to Rs 70 lakh to acquire shares in AMPYR Renewable Energy Resources Twelve A Private Limited, a subsidiary of AMPYR India Asset Holdings Two Pte. Ltd., Singapore, to avail renewable energy under a group captive open access arrangement for its Tarapur plant. The acquisition, expected to be completed within 12 months, will result in Valiant Laboratories holding up to 1.01% of the equity share capital and 3.60% of the compulsorily convertible preference shares of AMPYR, which was incorporated on November 1, 2023, and has a turnover of Rs 23.26 crore for the fiscal year ending March 31, 2026.

Valiant Laboratories Ltd announced that India Ratings and Research (Ind-Ra) has issued a credit rating to the company’s bank loan facilities, assigning an IND BBB rating to the INR 560 million bank loan facilities, along with a Stable Outlook and an IND A2 rating; the detailed rating rationale and instrument-wise rating actions can be accessed at https://www.indiaratings.co.in/pressrelease/85089, and this intimation has also been uploaded on the company’s website at www.valiantlabs.in.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, and open a new corporate office in Mumbai. Additionally, Valiant Laboratories intends to invest up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, to meet working capital needs.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, and open a new corporate office in Mumbai. Additionally, Valiant Laboratories intends to invest up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, to meet working capital needs.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506. Additionally, Valiant Laboratories approved an investment of up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, through the subscription of 1% Optionally Convertible Redeemable Preference Shares.

Valiant Laboratories Limited will hold a board meeting on Monday, August 10, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter ended June 30, 2026, according to a regulatory filing. The trading window for the company will remain closed until August 12, 2026, in accordance with SEBI regulations.

Net profit of Valiant Laboratories rose 151.43% to Rs 1.76 crore in the quarter ended March 2026 as against Rs 0.70 crore during the previous quarter ended March 2025. Sales rose 59.16% to Rs 91.98 crore in the quarter ended March 2026 as against Rs 57.79 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 3.27 crore in the year ended March 2026 as against net loss of Rs 2.20 crore during the previous year ended March 2025. Sales rose 78.04% to Rs 237.47 crore in the year ended March 2026 as against Rs 133.38 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales91.9857.79 59 237.47133.38 78 OPM %5.236.61 -2.69-3.50 - PBDT3.971.46 172 6.810.58 1074 PBT1.050.94 12 0.77-1.51 LP NP1.760.70 151 -3.27-2.20 -49 Powered by Capital Market - Live

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.